
What smart money is saying about Royalty Pharma
1 fund in our archive has pitched Royalty Pharma — most recently Cooper Investors Global Endowment in September 2025.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Position history
Between Q3 2025 and Q2 2026, 1 fund letter reported a position in Royalty Pharma, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q3 2025 | 0 | 0 | 0 | 1 |
Fund activity · 1 position
- HoldsLatitude Global FundJune 2026
“Our most recent addition in the healthcare sector, Royalty Pharma, continues to deliver on its medium-term plan.”
Read the letterRoyalty Pharma
Also mentioned · 1
These funds discuss Royalty Pharma — as a competitor, benchmark or comparable — without disclosing a position in it.
- June 2026
“Susannah Grey, formerly CFO of Royalty Pharma (RPRX) recently joined Anaptysbio’s board.”
Read the letterRoyalty Pharma
Fund coverage · 1 thesis
- Cooper Investors Global EndowmentSeptember 2025
Royalty Pharma generates consistent biotech and pharma IP royalties with expected pipeline growth and broader investor appeal after converting to a C-Corp.
Read the full thesis
Read every full thesis on Royalty Pharma
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→